(2017) found that distributions of Technetium macroaggregated albumin (Tc-MAA) particles used in the pretreatment dose-estimation procedure (with half the diameter of the therapeutic glass or resin spheres) differed only between 1.64% and 5.87% for the various catheter positions and cancer scenarios investigated. Here, ALB is linked to cancer.